The potential target conditions and diseases proposed by Crump [6] include myiasis, trichinosis, American- and African trypanosomiasis, asthma, and epilepsy, along with broader disease categories such as neurological, metabolically related, and Farnesoid X receptor (FXR)-mediated diseases. This evidence concerns the gene NR1H4 and human African trypanosomiasis.